# Anticancermiddelen verhogen risico op veneuze en arteriële trombose — Circulation

*geplaatst 2026-10-13 · Preventie · Circulation · doi 10.1161/CIRCULATIONAHA.125.079141 · https://hartvaat.nl/2026/10/06/anticancermiddelen-verhogen-risico-op-veneuze-en-arteriele-trombose-circulation/*

Deze review in Circulation beschrijft hoe diverse anticancermiddelen – van chemotherapie en hormonale therapie tot gerichte remmers – een verhoogd risico geven op veneuze en arteriële trombo-embolie bij kankerpatiënten. De auteurs schetsen de onderliggende pathobiologische mechanismen, benadrukken dat vasculaire bijwerkingen vaak worden onderschat, en vatten de huidige richtlijnadviezen voor risicostratificatie en preventie samen. Voor de cardioloog en internist is dit artikel essentieel voor het vroegtijdig signaleren en managen van drug-geïnduceerde vasculaire toxiciteit binnen de cardio-oncologie.

## English: Anticancer Drugs and Cancer-Associated Thrombosis.

This Circulation review examines how a broad spectrum of anticancer therapies, including chemotherapy, hormonal agents, and targeted inhibitors, significantly increases the risk of venous and arterial thromboembolism in cancer patients. The authors outline the underlying pathobiological mechanisms, highlight the frequent underestimation of vascular adverse events, and summarize current guideline recommendations for risk stratification and thrombosis prevention. For cardiologists and oncologists, these insights are crucial for proactive monitoring and management of drug-induced vascular toxicity in cardio-oncology practice.

## Abstract (original, from the publication)

The rapid development of novel cancer therapies has considerably improved the care of cancer patients and cancer-related survival; however, these therapies are associated with a broad range of adverse events that have become a major burden in this population. Alongside other cancer-related factors, vascular toxicity from anticancer therapies contributes to an increased risk of venous thromboembolism. Among anticancer drugs, chemotherapeutic agents (eg, anthracyclines, platinum-based drugs, antimetabolites), hormonal therapies (eg, selective estrogen receptor modulators), agents used for multiple myeloma (including immunomodulatory drugs and proteasome inhibitors), asparaginase, as well as targeted inhibitors to immune checkpoints, vascular endothelial growth factor, epidermal growth factor receptor, tyrosine kinases, cyclin-dependent kinases, and poly(ADP-ribose) polymerase are primarily associated with increased risk of venous thromboembolism. Vascular adverse events associated with anticancer drugs are frequently underestimated, and significant gaps remain in the risk stratification, prevention, and management of thromboembolic events in patients receiving systemic anticancer therapies. This review examines the evidence linking anticancer drug exposure to the incidence of venous thromboembolism, summarizes the key underlying pathobiological mechanisms, and highlights current guideline recommendations for the prevention and treatment of cancer-associated thrombosis. Arterial thrombotic events are also discussed where clinically or mechanistically relevant. This review also offers advanced cardio-oncology perspectives on the identification, risk stratification, and therapeutic targeting of drug-induced vascular toxicity.

Auteurs: Hessam Kakavand, Maryam Aghakouchakzadeh, Parham Sadeghipour, Armin Pasukanovic, Jean M Connors, Adam Cuker, Craig Beavers, Benjamin Van Tassell, Michelle Weisfelner Bloom, Behnood Bikdeli, Antonio Abbate, Nicola Potere, Jayant K Raikhelkar, Azita H Talasaz

---
Bron: Circulation, https://doi.org/10.1161/CIRCULATIONAHA.125.079141. Bijgewerkt 2026-10-06T01:09:02Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.